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ABSTRACT 
Critically ill patients often experience stress-induced hyperglycaemia, which results in increased 
morbidity and mortality. Glycaemic control (GC) can be implemented in the intensive care unit (ICU) to 
safely manage hyperglycaemia. Two protocols SPRINT and STAR, have been implemented in the 
Christchurch ICU, and have been successful in treating hyperglycaemia while decreasing the risk of 
hypoglycaemia. This paper presents a new GC protocol that implements the probabilistic, stochastic 
forecasting methods of STAR, while formalizing the control methodology using model predictive control 
(MPC) theory to improve the ability to tune the dynamic response of the controller. This Stochastic Model 
Predictive (STOMP) controller predicts the response to a given insulin/nutrition intervention, and 
attributes weighted penalty values to several key performance metrics. The controller thus chooses an 
intervention at each hour that minimizes the sum of these penalties over a prediction window of 6 hours, 
which is twice as long as the 3-hour window used in STAR. Clinically validated virtual trials were used to 
evaluate the relative performance of STOMP. Results showed STOMP was able to obtain results very 
similar to STAR with both protocols maintaining approximately 85% of time within 4.4-8.0 mmol/L 
glycaemic band, and only 4-5 patients of the 149 patient STAR cohort having blood glucose (BG) < 2.2 
mmol/L. STOMP was able to attain similar results to STAR while further increasing ease of controller 
tuning for different clinical requirements and reducing the number of BG measurements required by 35%. 
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INTRODUCTION 
Critically ill patients often experience stress-induced hyperglycaemia and high levels of insulin resistance 
[1-7]. The occurrence of hyperglycaemia, predominantly severe hyperglycaemia, is associated with an 
increase in morbidity and mortality in this group of patients [1, 3]. Glycaemic variability, and thus poor 
control, is also independently associated with an increase in mortality [8, 9].  
It has been shown that effective glycaemic control (GC) can significantly reduce the number of negative 
outcomes associated with poor control by modulating nutrition and/or insulin administration [7, 10, 11]. 
Effective GC can also lead to a reduction in the rate and severity of organ failure [12] and the cost of care 
[13, 14]. However, consistent, safe and effective GC remains elusive with several other studies achieving 
negative, or inconclusive outcomes [15-20]. In addition, there is little agreement on what constitutes 
desirable glycaemic performance [21-23], particularly with regard to how GC affects outcome. 
The model-derived SPRINT protocol has been successful at reducing organ failure and mortality [10, 12] 
with a patient-specific approach, providing the tightest control across all patients of several large studies 
[24, 25]. As a series of interactive charts, the SPRINT protocol allowed nutrition and insulin interventions 
to be tailored to current patient condition. However, as a paper-based protocol, SPRINT was relatively 
inflexible to different desired blood glucose targets and clinical uses, and required a relatively high nurse 
workload with 1-2 hourly blood glucose (BG) measurements. 
The Stochastic TARgeted (STAR) glycaemic control protocol was thus developed to address these issues 
[26, 27]. STAR recommends an intervention based on a clinically specified maximum risk of mild 
hypoglycaemia (e.g. BG < 4.4 mmol/L), derived from stochastic model predictions of future insulin 
sensitivity [28, 29]. With the ability to quantify the probability of hypoglycaemia, STAR allows 
aggressive yet safe control of blood glucose within a target band. STAR is flexible to different blood 
glucose targets [30, 31] and nursing intervention frequency, and thus, addresses many of the areas for 
improvement with the SPRINT protocol. However, the intervention selection algorithm used by STAR is 
fixed and does not allow for dynamic tuning, which limits the capacity for the controller to be further 
optimized in real time. 
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Model predictive control (MPC) is an alternative control approach that allows the dynamic response of the 
controller to be easily tuned through a series of clinically pre-defined cost functions. MPC utilizes a 
mathematical model of a system to forecast the response to a given input, and control interventions are 
chosen to produce optimal forecasted results. Commonly, optimization will involve specifying weighted 
(cost) functions to key input and output performance metrics, and choosing an intervention that minimizes 
the sum of these values. The benefit of such a system is that the cost functions can be easily optimized to 
produce robust and consistent control outcomes from an intuitively easily understood clinical 
specification. This type of controller was chosen due to the flexibility of cost functions in allowing the 
dynamic response of the controller to be easily tuned. MPC has also been used for glycaemic control with 
a different model [32-35]. 
This article presents a Stochastic Model Predictive (STOMP) GC protocol that uses a low error, 
infrequently measured, BG signal to control the BG levels in adult ICU patients while providing greater 
flexibility than STAR. This research presents the protocol design and optimization for an adult ICU using 
clinically validated [36] virtual trials to amend safety and efficacy before clinical uptake. 
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METHODS 
Glucose-Insulin Model 
A variant of the ICING model [37] was used to describe glucose-insulin metabolic system dynamics:  
?̇?(𝑡) = −𝑝𝐺𝐺(𝑡) −  𝑆𝐼(𝑡)𝐺(𝑡)
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 (3) 
𝑃(𝑡) = min(𝑑2𝑃2, 𝑃𝑚𝑎𝑥) + 𝑃𝑁(𝑡) (4) 
?̇?1(𝑡) = −𝑑1𝑃1 + 𝐷(𝑡) (5) 
?̇?2(𝑡) = −min (𝑑2𝑃2, 𝑃𝑚𝑎𝑥) + 𝑑1𝑃1 (6) 
𝑢𝑒𝑛(𝐺) = min (max (𝑢𝑚𝑖𝑛, 𝑘1𝐺(𝑡) + 𝑘2), 𝑢𝑚𝑎𝑥) (7) 
 
The key variables are described in Table 1, while the remaining model parameters, rates and constants are 
described in [37] and [38]. 
Table 1: Key variables of metabolic glucose model. 
Variable Unit Description 
G(t) mmol/l Blood glucose concentration 
I(t) mU/l Plasma insulin concentration 
Q(t) mU/l Interstitial insulin concentration 
P(t) mmol/min Glucose appearance in plasma from dextrose intake 
SI(t) l/mU/min Insulin sensitivity 
  
This model-based insulin sensitivity, SI(t) (SI), has been shown to be independent of both insulin and 
nutrition inputs, and can be used to calculate the likely BG response to treatments other than those given 
clinically. This process is called a virtual trial, and has been clinically validated to describe both whole 
cohort and per-patient results [36].  
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Stochastic Model 
Forward prediction of BG is enabled by an estimate of the conditional probability density function of SI 
based on historical data (stochastic model). The stochastic model used by STAR is generated using kernel-
density methods and model-based insulin sensitivity data from a large cohort of patients (43,000 SI values 
from approximately 400 patients). Given a value of SI (at time n), the stochastic model can be used to 
estimate the probability of future SI values (at time n+1). 
 
Figure 1: Stochastic model of insulin sensitivity. 
 
STAR focusses on the 5th- and 95th-percentile values, as these values can be used to impose a 5% risk limit 
on hypoglycaemia for a given insulin/nutrition intervention. Figure 2 indicates the relationship between 
the insulin sensitivity and the associated blood glucose trajectory. The model covers a broad medical ICU 
cohort over all the days of stay, but can be made specific to unique cohorts [39, 40]. 
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Using the insulin sensitivity stochastic model obtained from Figure 1 the BG stochastic model, for a 
specific insulin and nutrition intervention, can be obtained through solving the Glucose-Insulin model. 
The BG stochastic model is used to predict the trajectory of the patients BG, as seen in the right of 
 Figure 2. 
Cost functions 
The cost functions used to evaluate the multiple different interventions can be seen in Figure 3. These cost 
functions were chosen iteratively using virtual trials to evaluate the likely results from an individual set of 
functions. They are also strongly based on clinical and physiological literature and clinical experience 
with prior protocols. The functions are designed to manage risk tradeoffs between BG outcomes, and the 
insulin and nutrition interventions.  
The 5th- and 95th-percentile BG cost functions are based on BG predictions with given interventions and 
an associated predicted SI value from the stochastic model. These functions were designed to severely 
penalize both hyper- and hypo- glycaemia, and thus keep the predicted 5th- and 95th-percentile BG range 
within a desirable band [41]. The 5th-percentile BG cost function was generated by a combination of 
functions, severely penalizing BG < 4 mmol/L while not forcing the controller to be too aggressive in 
lowering BG, ensuring hypoglycaemia was very unlikely to occur. Thus, the 95th-percentile BG cost 
Figure 2: Using the stochastic model of insulin sensitivity to find the stochastic model of blood glucose trajectory for a 
given insulin and nutrition intervention. 
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function is compromised to put greater emphasis on reducing the incidence of hyperglycaemia. The 
equations for the two cost functions can be seen in Equation (8) and (9). 
  𝐶𝑜𝑠𝑡𝐵𝐺5 = 1.875 ∗ 𝐵𝐺5𝑡ℎ
2 − 16.5 ∗ 𝐵𝐺5𝑡ℎ + 36.3 + 𝑒
(−10∗𝐵𝐺5𝑡ℎ+42)  ( 8 ) 
     𝐶𝑜𝑠𝑡𝐵𝐺95 = 0.1 ∗ 𝐵𝐺95𝑡ℎ
2    ( 9 ) 
Figure 3: Cost functions used to evaluate the optimal intervention. 
 
The insulin and nutrition cost functions were designed to maximize nutrition and minimize insulin use. 
This choice ensures the patient is getting as much of a desired goal nutrition rate as possible to get 
sufficient nutrients for recovery, while minimizing the chance of BG falling dramatically due to the large 
insulin doses amplifying the effects of insulin sensitivity variability. Hence, it is a balance weighted 
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towards nutrition intake and safety. The equations for the two cost functions can be seen in Equation (10) 
and (11). 
  𝐶𝑜𝑠𝑡𝐼𝑁𝑆 = 0.0011 ∗ 𝐼𝑛𝑠𝑢𝑙𝑖𝑛
2 − 0.0775 ∗ 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 + 1.255   ( 10 ) 
𝐶𝑜𝑠𝑡𝑁𝑈𝑇 = 1.1719𝑒4 ∗ %𝐺𝐹
4 − 1.901𝑒4 ∗ %𝐺𝐹3 + 1.1697𝑒4 ∗ %𝐺𝐹2 − 3.2726 ∗ %𝐺𝐹 + 356.0714 ( 11 ) 
Pancreatic insulin secretion in the critically ill can be highly variable and unpredictable. Thus, maintaining 
a low insulin infusion rate can dominate pancreatic insulin secretion [42] and provide greater certainty 
around circulating plasma insulin for model-based predictions. Hence, the minimum of the insulin cost 
function is placed at 2 U/hr (33 mU/min) to increase this predictability.  
The mathematical equations for the cost functions were derived by fitting either a 2nd or 4th order 
polynomial to the desired clinical shape. The cost function polynomials were designed to have a clear 
global minima in the range at which the functions would be applied. The use of polynomials meant the 
cost functions were smooth, thus meaning convergence to the global minimum was regular. An 
exponential term was added to the BG 5th Cost function to severely penalise hypoglycaemia. 
Cost function weightings 
Weightings were placed on each of the evaluated cost functions to increase the relative importance of 
certain variables and factors. The costs of the hourly BG predictions, evaluated up to the prediction 
horizon, were weighted so that the weighting increased as the blood glucose prediction time increased. A 
normalized weighting sum was maintained of this cost value, defined.  
𝑊𝑖 = (
2
𝑁
−
1
∑ 𝑗𝑁𝑗=1
)
𝑖
𝑁
     ( 12 ) 
Where:             𝑊𝑖 = 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑖𝑛𝑔 𝑤𝑖𝑒𝑔ℎ𝑡 
𝑖 = 𝐵𝐺 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛 ℎ𝑜𝑢𝑟 ( 𝑖 = 1 − 6 ℎ𝑜𝑢𝑟𝑠) 
𝑁 = 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛 𝑤𝑖𝑛𝑑𝑜𝑤 𝑝𝑒𝑟𝑖𝑜𝑑 (6  ℎ𝑜𝑢𝑟𝑠) 
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In addition to the time dependent normalized weighting of BG predictions, an additional weighting was 
placed on the blood glucose prediction costs. This weighting ranks the BG prediction costs higher than the 
insulin and nutrition costs. Iteratively, it was found that a weighting multiplier of 6 on the BG prediction 
costs gave the best performance, while maintaining reasonable nutrition and insulin levels with this overall 
model-based approach. 
Prediction horizon  
Prediction horizons of 1 to 10 hours were initially investigated. For simplicity, the nutrition and insulin 
interventions chosen are kept constant over the finite prediction horizon. This design choice was made to 
restrict the BG variability introduced by unexpected controller behaviour. Insulin and nutrition changes 
have differing timescales, with insulin changes having a rapidly observable effect (<10 minutes), while 
enteral nutrition changes act over 1-2 hours due to the slower, more complex absorption dynamics through 
the stomach and gut. Thus, BG outcomes over longer prediction horizons include greater contribution 
from changes in enteral nutrition. 
Initial simulations highlighted two factors that limited the prediction horizon. Insulin sensitivity fluctuates 
each hour, and thus the current fitted SI value becomes more inaccurate as the prediction horizon 
increases. Additionally, constant insulin and nutrition over the interval means the model reaches a steady-
state value over time. Typically, steady-state was reached after approximately 6 hours, thus limiting the 
maximum horizon. As a result, a prediction horizon of 6 hours was chosen.  
To ensure all the evaluated costs of 5th- and 95th-percentile BG had equal weightings for each prediction 
horizon tested, relative to the other parameters, the total cost for the 5th- and 95th-percentile BG was set to 
the average of the costs evaluated at each hour over the prediction horizon. This summation over 6 hours 
effectively awards consistent BG within the band.  
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Patient Cohort and virtual trials 
Clinical data from 149 patients treated with the STAR protocol (2011-2014) [26, 30], in Christchurch 
Hospital ICU were used to generate virtual patients. Details of these patients are shown in Table 2. The 
Upper South Regional Ethics Committee, New Zealand granted approval for the audit, analysis and 
publication of this data. 
Virtual patients were created from the patient-specific time varying model-based insulin sensitivity 
profiles [43]. This model-based insulin sensitivity can be used as a critical marker of patient metabolic 
state [29, 36, 44]. These virtual patients allow robust protocols to be safely designed and rigorously tested 
prior to clinical implementation, improving patient safety and minimising the need for protocol alterations 
post- implementation [36]. Performance and safety were assessed by whole-cohort %BG in glycaemic 
bands, and the %BG and number of patients with hypoglycaemia. 
 
Table 2: STAR cohort details. Data are presented as median (interquartile range) where appropriate 
  Number of Patients, N 149 
Age (years) 64 (54-72) 
Gender (% Male) 66.7 
Length of ICU Stay (days) 8.4 (3.5-16.0) 
Operative/Non-operative 49/100 
APACHE II score 21.0 (15.0 – 25.0) 
Length of glycaemic control 
(hours) 
73.4 (43.2-135.7) 
Cohort total glycaemic control 
(hours) 
17,610 
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RESULTS 
Table 3 presents a comparison of the performance of STAR and STOMP on the STAR cohort. STAR 
clinical data is presented for comparison with virtual trials using bolus insulin. An infusion-based virtual 
trial of STAR is also presented for direct comparison with the infusion-based STOMP protocol. Both 
STAR and STOMP allow variable measurement intervals, based on BG history. The value in Table 4 
represents the maximum allowed measurement interval. Clinically, STAR uses a 3-hour maximum 
interval. 
 
Table 3: Clinical and virtual trial performance for STAR and STOMP on STAR Cohort. STAR Bolus Clinical 
shows actual clinical performance of STAR. The other columns indicate virtual trial performance on 
this same cohort using bolus or infused insulin, with maximum measurement intervals as indicated. 
 
STAR Bolus 
Clinical 
STAR Bolus 
3hr max meas. 
STAR Infusion 
3hr max meas. 
STOMP Infusion 
3hr max meas. 
STOMP Infusion 
4hr max meas. 
Average number of  
measurements per day 
13.4 13.2 12.7 10.0 8.4 
% time 
BG 4.4 - 7 mmol/L 61.0 75.4 73.2 76.8 73.5 
% time  
BG 4.4 - 8.0 mmol/L 80.6 87.5 86.3 87.7 86.2 
% time  
BG 8.0 - 10 mmol/L' 12.6 7.9 8.6 7.7 8.2 
% time  
BG > 10 mmol/L' 5.1 2.5 2.6 3.2 3.2 
% time  
BG < 4.4 mmol/L 1.7 2.7 3.2 1.9 2.8 
% time 
BG < 2.2 mmol/L 
0.006 0.01 0.05 0.04 0.06 
Number of Patients 
BG < 2.2 
3 2 4 4 5 
Median Goal Feed  
[IQR] (%) 
75.9 
 [36.4 - 99.4] 
 
90.2 
[30.7-100.0] 
 
84.8 
[30.5- 100.0] 
 
80.0 
[65.0 - 95.0] 
80.0 
 [65.0 - 95.0] 
Median insulin rate  
[IQR] (U/hr) 
2.5  
[1.0 - 4.0] 
 
3.0  
[1.5 - 5.5] 
 
4.0 
 [1.5 - 6.0] 
 
4.0  
[2.0 - 5.5] 
4.0 
 [2.0 - 5.5] 
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A randomly selected patient was chosen to show how the different controllers respond to fluctuating 
insulin sensitivity. Figure 4 shows this example and also shows how the total cost calculated by STOMP 
varies during a simulation. While overall the BG is largely similar, insulin interventions vary significantly, 
illustrating the differences between approaches.  
 
  
Figure 4: Example showing the performance of STOMP and STAR (Bolus) on a patient. The target glycemic 
band (4.4-8.0 mmol/L) is shaded green in the top panel 
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DISCUSSION 
From the results it can be seen that the STOMP controller worked very well giving glycaemic results 
approximately equal to that of both STAR controllers. Both STAR and STOMP protocols demonstrated 
good performance. The percentage of time BG in band was relatively high, while also ensuring safety 
from hypoglycaemia (< 0.1% time below 2.2 mmol/L). Numbers of patients with BG < 2.2 mmol/L (4-5 
patients) were lower than any reported study, where rates of 10-20% by patient have been reported [17, 
45, 46]. Because STOMP optimises treatment and performance over a 6 hour window, it able to maintain 
excellent control performance with 4 hour measurement intervals. Hence, the average number of 
measurements per day and thus nurse GC workload are reduced by approximately 35%. 
Figure 4 shows the total penalty cost for the chosen intervention in the bottom panel. STOMP can be seen 
to always be trying to minimize the intervention cost, and thus target an optimum balance of outcome-BG 
and intervention for the patient, based on the pre-selected weights and penalty functions. When the insulin 
sensitivity decreases, insulin becomes less effective and, as a consequence, larger interventions must be 
used to obtain the desired BG. This behaviour and choice causes a general increase in cost for all the 
potential interventions at that hour.  
The method of using a combination of cost functions, long prediction horizon, stochastic prediction of 
variability, and a mathematical model to implement a glycaemic control protocol has proven to be very 
effective. This approach formalizes the STAR control algorithm, making it easier to optimize for different 
clinical requirements. Using cost functions to select the response of the controller means that changes in 
the response can be easily adapted to put a higher priority on any of the desired performance metrics, as 
clinically specified. Thus, clinical staff could choose the weighting for each performance metric based on 
the specific patient’s condition or local practice, making the protocol more patient-specific or hospital-
specific. For example, if a patient was hyperglycaemic, but the clinicians wanted to continue giving the 
patient a high amount of nutrition, the cost functions could be adapted so there was a larger penalty for 
having low nutrition, thus causing the controller to have to choose an intervention which had a higher 
nutrition input, while also trying to maintain a desirable BG. 
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Additional cost functions, based on other aspects of glycaemic control, could be easily added to STOMP. 
This is a level of flexibility that is not currently available with the STAR protocol. For example, adding a 
cost function to reduce large changes in insulin interventions would make the controller less likely to over 
respond and suit a more cautious clinical practice. The MPC cost functions enabled this added flexibility 
in implementing a stochastic-predictive controller. STOMP is then potentially better suited for a more 
diverse range of clinical practice cultures and cohort-specific approaches than STAR. 
It is also important to note that this MPC form of STAR is different than eMPC [47]. Beyond a different 
model, it uses stochastic model forecasting [28, 29] to manage intra-patient metabolic variability and risk 
[24, 48]. In contrast, eMPC uses auto-regressive models that are more patient-specific but require more 
data to adapt to changes. As a result this MPC approach (as with STAR) can safely predict further ahead 
because it does not rely on external black- or grey-box machine learning models to manage intra-patient 
variability. 
The results of these virtual trials suggests that STOMP is ready for a pilot clinical trial. A pilot trial will 
validate these results on real patients prior to full clinical implementation. 
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CONCLUSIONS 
An MPC glycaemic control protocol was developed and optimised for an adult BG signal in the ICU using 
the virtual trial approach. The STOMP protocol was designed as a model-predictive evolution of STAR 
that permits controller response to be easily tuned to specific, clinically relevant performance metrics. It 
has the additional benefit of formalising the heuristic control algorithm of STAR, and being a much more 
generalisable approach. The results indicate STOMP retains the performance and safety of STAR with 
approximately 85% time in the 4.4-8.0 mmol/L glycaemic band and 0.06% time < 2.2 mmol/L, with 35% 
fewer BG measurements. This protocol is a promising start that enables the development a more easily 
customized GC alternatives within an existing, proven model-based GC framework.  
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